Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Immune Design
Information provided by (Responsible Party):
Immune Design Identifier:
First received: December 13, 2013
Last updated: June 27, 2014
Last verified: June 2014

This is a Phase I, multi-center, multiple ascending dose study to evaluate the clinical safety and immune response of IDC-G305 when injected intramuscularly in patients with unresectable or metastatic cancer. IDC-G305 is an immunotherapy consisting of recombinant NY-ESO-1 antigen and the adjuvant, GLA-SE. The goal is for IDC-G305 to stimulate the body's immune system to fight the spread and growth of cancer for patients whose tumors include the NY-ESO-1 protein. Patients with melanoma, ovarian, renal cell or non-small cell lung cancer may be considered for the trial.

Condition Intervention Phase
Ovarian Cancer
Non-small Cell Lung Cancer
Breast Cancer
Biological: IDC-G305
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer

Resource links provided by NLM:

Further study details as provided by Immune Design:

Primary Outcome Measures:
  • Safety and tolerability [ Time Frame: Up to 1 year after last vaccination ] [ Designated as safety issue: Yes ]
    To evaluate the safety and tolerability of multiple ascending doses of intramuscular (IM) IDC-G305

Secondary Outcome Measures:
  • Immunogenicity [ Time Frame: Approximately 12 weeks ] [ Designated as safety issue: No ]
    The secondary objective is to evaluate the humoral and cellular immunogenicity of multiple ascending doses of intramuscularly administered IDC-G305

Estimated Enrollment: 30
Study Start Date: November 2013
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IDC-G305
NY-ESO-1 recombinant protein together with GLA-SE
Biological: IDC-G305
NY-ESO-1 recombinant protein together with GLA-SE

Detailed Description:

This is a Phase 1, open label, multicenter, multiple ascending dose trial of IDC-G305 administered by intramuscular injection in a 3+3 sequential dose escalation design. IDC-G305 is an immunotherapy consisting of recombinant NY-ESO-1 antigen and the adjuvant, GLA-SE. Patients with unresectable, relapsed or metastatic cancer but with low disease burden and indolent disease course may be considered for the trial. Tumors must express the NY-ESO-1 gene signature and tumor types that will be studied are: melanoma, ovarian, sarcoma,non-small cell lung and breast cancer.

Each of three dose level cohorts will be treated contingent upon absence of dose limiting toxicity (DLT) and acceptable safety data for the preceding cohort. Initially, three patients will be scheduled to receive IDC-G305 in each dose level cohort. Dose escalation will be contingent upon the assessment of safety data obtained during the initial injections.

Patients will be evaluated at baseline and at regular intervals for safety and immune response. Both cellular and humoral immunogenicity will be explored.


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of melanoma, ovarian cancer, sarcoma, breast cancer or non-small cell lung cancer (NSCLC)
  • Unresectable, relapsed and/or metastatic cancer with minimal or low disease burden. Disease may or may not be measurable and should not be rapidly progressive. Inadequate response, relapse and/or unacceptable toxicity with one or more prior systemic, surgical, or radiation cancer therapies, except patients with NSCLC and breast cancer who must have experienced an inadequate response and/or unacceptable toxicity with two or more prior systemic, surgical, or radiation cancer therapies.
  • Cancer expresses NY-ESO-1
  • ≥ 18 years of age
  • Life expectancy of ≥ 6 months
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • ECG without evidence of clinically significant arrhythmia or ischemia
  • Negative pregnancy test for females of childbearing potential

Exclusion Criteria:

  • Pregnant or nursing
  • Vaccine or other therapy directed against NY-ESO-1 at any time in the past and any investigational therapy within three weeks prior to IDC-G305 dosing
  • Significant immunosuppression
  • Cancer chemotherapy, G-CSF or GM-CSF within three weeks prior to the first study treatment
  • Significant autoimmune disease
  • Myocardial infarction within six months of treatment, active cardiac ischemia or Grade III or IV heart failure
  • Inadequate hematology or chemistry profiles
  • History of other cancer within three years
  • Active, concurrent or recent infection, including tuberculosis, hepatitis B, hepatitis C or HIV
  • Uveal melanoma
  • Brain metastases considered unstable
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02015416

Contact: Immune Design 650-887-6703

United States, Arizona
Scottsdale Healthcare Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Molly Downhour, RN    480-323-1357   
Principal Investigator: Sam Ejadi, MD         
United States, Florida
H. Lee Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Nancy Burke    813-745-4616   
Principal Investigator: Amit Mahipal, MD         
United States, Michigan
Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Clarice Zuccaro    313-576-9375   
Principal Investigator: Shelly Seward, MD         
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Francine Siedlecki, RN    716-845-1439   
Principal Investigator: Kunle Odunsi, MD         
Sponsors and Collaborators
Immune Design
Principal Investigator: Kunle Odunsi, MD PhD Roswell Park Cancer Institute
  More Information

No publications provided

Responsible Party: Immune Design Identifier: NCT02015416     History of Changes
Other Study ID Numbers: IDC-G305-2013-001
Study First Received: December 13, 2013
Last Updated: June 27, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Immune Design:
Ovarian cancer
Non-small cell lung cancer
Breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasm Metastasis
Ovarian Neoplasms
Adnexal Diseases
Breast Diseases
Bronchial Neoplasms
Carcinoma, Bronchogenic
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Lung Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neoplastic Processes
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Ovarian Diseases
Pathologic Processes
Respiratory Tract Diseases processed this record on November 25, 2014